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Background: Hepatic metastasectomy for patients with primary colorectal cancer offers better long-term outcome,
and chemotherapy can increase the rate of hepatic resectability for patients with initially inoperable disease. The
pattern of liver metastasis and status of the primary tumor are rarely discussed in the analysis of long-term
outcome. In this report, we evaluate the influence of the pattern of metastasis on clinical features and prognosis.
Methods: One hundred and fifty-nine patients who underwent hepatic metastasectomy with curative intent for
liver metastasis of colorectal cancer between October 1991 and December 2006 were enrolled. Patients were
grouped according to whether liver metastasis was centrally or peripherally located, based on imaging and
operative findings. Patient demographics, characteristics of the primary and metastatic tumors, and surgical
outcomes were analyzed for long-term survival.
Results: A greater proportion of patients with centrally located metastases were male, as compared with those
with peripherally located metastases. Compared with patients with peripherally located metastases, patients with
centrally located metastases were more likely to have multiple lesions (P = 0.016), involvement of multiple
segments (P = 0.006), large metastases (P < 0.001), and bilobar distribution of metastases (P < 0.001). The estimated
5-year recurrence-free and overall survival rates were 22.4% and 34.2%, respectively. Univariate analysis revealed that
centrally located metastasis, primary tumor in the transverse colon, metastasis in regional lymph nodes, initial
extrahepatic metastasis, synchronous liver metastasis, multiple lesions, poorly differentiated tumor, and resection
margin <10 mm were significant poor prognostic factors for recurrence-free survival and overall survival. Cox
regression analysis showed that inadequate resection margin and centrally located liver metastasis were significant
predictors of shorter overall survival.
Conclusions: In colorectal cancer, centrally located liver metastasis represents a poor prognostic factor after
hepatectomy, and is associated with early recurrence. Neoadjuvant chemotherapy may be used to downstage
centrally located liver metastases to improve outcome.
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Half of all patients with colorectal cancer (CRC) develop
liver metastases in the course of this disease [1-3]. Patients
with colorectal liver metastases (CRLM) may benefit from
liver resection because it provides an opportunity for cura-
tive management by means of repeated or staging hepatec-
tomy [4-9]. Surgical strategies for CRLM and combined
treatment to increase hepatic resectability in order to im-
prove long-term outcome were reported by Adam et al.
[10-14]. Earlier analyses of prognosis reported that mul-
tiple hepatic metastatic lesions, node-positive primary
tumor, poorly differentiated primary tumor, extrahepatic
spread, larger tumor size, higher carcinoembryonic anti-
gen (CEA) level, and positive resection margin were sig-
nificant predictors for shorter survival [15]. High CEA
level, venous invasion, and tumor budding predicted ex-
trahepatic recurrence after partial hepatectomy [16]. Fong
et al. incorporated seven independent, significant predic-
tors into a statistical model with a formula based on a
1,001 consecutive cases [17]. For patients undergoing hep-
atectomy for CRLM, achieving a resection margin of >1
cm has become standard in current clinical practice
[18-20]. Adjuvant or salvage treatment with oxaliplatin-
based or irinotecan-based regimen has been shown to im-
prove outcome [21]. Whether the location of hepatic
metastatic lesions influenced prognosis was rarely dis-
cussed. Centrally located liver metastases may affect the
results of hepatectomy because of the restrictions of anat-
omy, technical difficulties in surgical approach, and mor-
bidity resulting from surgery. Little is known about the
differences between CRLM with central versus peripheral
location with regard to characteristics of the primary
tumor, characteristics of metastatic tumor, and the clinical
course after liver resection.
The aim of the study was to compare the clinicopatho-
logic characteristics, timing of recurrence, and surgical
outcome in patients with centrally or peripherally lo-
cated colorectal liver metastasis. Medical records of con-
secutive patients with CRLM undergoing potentially
curative liver resection at our institution were reviewed




One hundred and fifty-nine patients who underwent liver
resection with curative intent for resectable CRLM were
enrolled in this retrospective study at Chang Gung Me-
morial Hospital Linkou Medical Center (Taoyuan, Taiwan)
between October 1991 and December 2006, with a follow-
up period ranging from 0.9 to 246.6 months (median: 38.5
months). Coexistent extrahepatic lesions or intrahepatic
lesions after downstaging by neoadjuvant chemotherapy
were evaluated to confirm resectablility. Patients weredivided into two groups based on the location of hepatic
metastases, either central or peripheral. Central metastases
were defined as those located at the first or second gener-
ation of hepatic bifurcation (close to the hepatic hilum).
Patients with concurrent central and peripheral lesions
were grouped with patients who had only central metasta-
ses. The metachronous lesion was defined as a lesion aris-
ing 3 months or more after resection of the primary
colorectal cancer [22,23]. With the approval of the institu-
tional review board (IRB 98-1881B), the clinicopathologi-
cal characteristics, surgical management, and long-term
outcomes of patients were analyzed and compared be-
tween the two groups.
Hepatic resection for CRLM
For assessment of the clinical status of the primary colorec-
tal cancer and liver metastasis, all patients underwent full
evaluation with appropriate studies including chest roent-
genography, abdominal computed tomography (CT), and/or
liver ultrasonography before surgery. Hepatic resection with
curative intent was defined as complete resection of all hep-
atic metastatic lesions with preservation of a sufficient liver
remnant. In order to achieve better resection margins and to
avoid unnecessary damage to vital structures, intraoperative
ultrasonography was performed for localization of the tu-
mors and to visualize the spatial relationship to Glisson’s
sheath. Liver resections were performed using either the
clamp-crush technique or the Cavitron Ultrasonic Surgical
Aspirator (CUSA; Valleylab, Inc., Boulder, CO, USA). Hilar
inflow control was not routinely applied for the transection
of liver parenchyma. Patients received postoperative follow-
up and were monitored for tumor recurrence by means of
physical examination, serum CEA levels, and abdominal
ultrasonography once every 3 months thereafter. Advanced
image studies, including CTscan and/or magnetic resonance
imaging (MRI) of the chest, abdomen, and pelvis, were per-
formed when cancer recurrence was suspected.
Data collection and statistical analysis
Information on demographics, characteristics of the pri-
mary and metastatic tumor, surgical details, and hospital
course was collected from medical records. Patients who
died within 30 days of liver resection or during the same
hospitalization were considered to have suffered surgical
mortality. Recurrence after liver resection was defined as
the presence of a new lesion detected by an imaging
study or a new lesion characterized by histological exam-
ination from either biopsy or surgical resection.
Statistical analyses were conducted using the statistical
software SPSS 20.0 (IBM Corp., Armonk, NY, USA).
Outcome measures included recurrence-free survival
(RFS) and overall survival (OS) after liver resection. The
χ2 test was used to compare clinicopathologic features.
Continuous data were presented as the mean ± standard
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RFS and OS were estimated using the Kaplan-Meier
method, and any significant difference between the sub-
groups noted by univariate analysis was compared using
the log-rank test. Multivariate analysis was conducted
with the Cox regression. A P value of < 0.05 was defined
as statistically significant.
Results
The characters of primary tumor, liver metastasis, and
interval of resection in patients with central or peripheral
metastases
One hundred and fifty of 159 patients (94.3%) were
followed for more than 6 months after liver resection.
Twenty-four patients (15.1%) presented with central
liver metastases, while 135 patients (84.9%) had periph-
eral metastases. Table 1 summarizes demographic data.
There were no significant differences in clinical charac-
teristics between the two groups except for gender; men
comprised a larger proportion of patients in the group
with central metastases (79.2% vs. 51.9%, P = 0.014).
There was no significant difference between the two
groups in primary tumor location, tumor staging, re-






Age (year) 58.5 ± 2.4 (29–75)
Location of the primary tumor(s)
Rectum 13 (54.2%)
Sigmoid colon 6 (25.0%)
Descending colon 1 (4.2%)
Transverse colon 3 (12.5%)
Ascending colon and cecum 1 (4.2%)
Synchronousa 0 (0.0%)
Primary tumor staging
T1 or T2 2 (8.3%)
T3 7 (29.2%)
T4 15 (62.5%)




Primary extrahepatic metastasis 6 (25.0%)
Associated risky presentation(s)b 5 (20.8%)
aSynchronous: two or more primary colorectal cancers identified at the same time; bAs
or both.perforation, but 18 patients (11.3%) had concurrent ex-
trahepatic metastases at the time of hepatectomy (cen-
tral vs. peripheral group, 25.0% vs. 8.9%, P = 0.033).
There were additional significant differences between
the two groups with regard to liver metastases. The max-
imum diameter of the largest metastasis was greater in the
group with central lesions (5.9 ± 0.8 vs. 3.0 ± 2.4 cm). Sig-
nificant poor prognostic factors were more prevalent in
the group with central lesions. These factors included the
involved segment, lobar distribution, and number of me-
tastasis. Hepatic metastases occurred synchronously in
104 patients (65.4%), and there was no difference between
the two groups with regard to synchronicity. In addition,
serum CEA level prior to hepatectomy and the degree of
differentiation of metastatic lesions were not statistically
significant; however, the CEA level was somewhat greater
in the group with central lesions (366 ± 205 vs. 109 ± 53
ng/ml, P = 0.095) (Table 2).
Management and surgical results
Fifteen patients (9.4%) received neoadjuvant chemother-
apy with 5-fluorouracil-based regimens. Disease progres-
sion occurred in nearly three quarters of all patients in
the present study. Anatomic resection with curativerimary tumor(s)



















sociated risky presentation(s) included obstruction, tumor rupture/perforation,
Table 2 The characteristics of liver metastasis
Centrally located Peripherally located P values
(n = 24) (n = 135)
CEA level before hepatectomy (ng/ml) 366.2 ± 205.5 (0.88 to 4,280.0) 109.9 ± 53.2 (0.50 to 7,025.0) 0.095
Interval of hepatic metastasisa
Synchronous 17 (70.8%) 87 (64.4%) 0.544
Metachronous 7 (29.2%) 48 (35.6%)
Involved segment(s)
Single 3 (12.5%) 56 (41.5%) 0.006
Multiple 21 (87.5%) 79 (58.5%)
Lobar distribution
Unilobar 6 (25.0%) 108 (80.0%) 0.000
Bilobar 18 (75.0%) 27 (20.0%)
Maximal diameter of the largest metastasis (cm) 5.9 ± 0.8 (1.2 to 17.9) 3.0 ± 2.4 (0.3 to 10.8) 0.000
Number of metastasis
Solitary 10 (41.7%) 91 (67.4%) 0.016
Multiple 14 (58.3%) 44 (32.6%)
Differentiation of metastasis
Well 5 (20.8%) 10 (7.4%) 0.113
Moderately 18 (75.0%) 120 (88.9%)
Poorly 1 (4.2%) 5 (3.7%)
aThe metachronous type was defined as when the metastasis was noted for 3 months or more after resection of primary colorectal cancer.
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or lesions that were difficult to resect, but there was no
difference between the two groups (29.2 vs. 18.5%, P =
0.27). In the group with central lesions, 41.7% of patients
had resection margin involved with tumor even though
surgical resection was performed with attention to
achieving a grossly negative margin (P = 0.003). There
was no difference in the recurrence pattern between the
two groups, but patients whose metastases were cen-
trally located were more likely to have early recurrence,
with an interval of less than 4 months (37.5% vs. 17.8%,
P = 0.032). One patient with peripheral metastatic tumor
died in the hospital because of leakage at the anasto-
motic site and resultant sepsis; however, the liver resec-
tion per se was without intraoperative or postoperative
complication (Table 3).
Recurrence-free and overall survival
For all patients in this study, the median time to recur-
rence was 10.4 months, and median survival time was
36.0 months. The estimated 5-year recurrence-free sur-
vival rate was 22.4%, and 5-year overall survival rate was
34.2%. Univariate analysis of prognostic factors for
recurrence-free and overall survival revealed that the pa-
tients with central metastases had shorter recurrence-
free (P = 0.017) and overall survival (P = 0.002) than did
those with peripheral metastases (Figure 1). Primary
tumor of the transverse colon, regional lymph nodemetastasis, primary extrahepatic metastasis, synchronous
liver metastasis, multiple lesions and poorly differenti-
ated metastatic lesions, and hepatectomy with margin of
resection <10 mm were prognostic factors for shorter
recurrence-free and overall survival in univariate ana-
lysis. In addition, advanced status of the primary tumor
(T4), presentation with obstruction or perforation, in-
volvement of multiple segments, and the presence of a
metastatic lesion >5 cm in diameter were significant
prognostic factors for shorter overall survival (Table 4).
Cox regression analysis demonstrated that primary posi-
tive lymph node status, primary extrahepatic metastasis,
synchronicity, central type hepatic metastasis, high grade
of liver metastatic lesion, and resection margin of <1 cm
all were independent significant prognostic factors that in-
fluenced overall survival. Each of these factors, except for
primary extrahepatic metastasis and central location of le-
sions, was associated with worse prognosis in recurrence-
free survival (Table 5). The estimated recurrence-free and
overall survival curves based on each independent prog-
nostic factor are shown in Figures 2 and 3.
Discussion
The location of liver metastasis from CRC might affect the
surgical planning. In this series, most metastases were per-
ipheral. Therefore, a single segmentectomy or subsegmen-
tectomy, by Brisbane classification, was the most common
surgical strategy. The outcome was relatively good even in
Table 3 Management, resection margin, and recurrence status after hepatectomy
Centrally located Peripherally located P values
(n = 24) (n = 135)
Neoadjuvant chemotherapy 4 (16.7%) 11 (8.1%) 0.247
Effective (stable, partial/complete response 0 (0.0%) 4 (36.4%) 0.159
Progression 4 (100%) 7 (63.6%)
Anatomic resectiona 7 (29.2%) 25 (18.5%) 0.269
Resection margin (mm)
Involved 10 (41.7%) 20 (14.8%) 0.003
<10 mm 13 (54.2%) 85 (63.0%)
≥10 mm 1 (4.2%) 30 (22.2%)
Recurrence after hepatectomy 22 (91.7%) 100 (74.1%) 0.045
Confined in the liver, lung, or both 7 (31.8%) 31 (31.0%) 1.000
Recurrence in other distant organ(s) 15 (68.2%) 69 (69.0%)
Early recurrenceb 9 (37.5%) 24 (17.8%) 0.032
Repeated hepatectomy 1 (4.2%) 13 (9.6%) 0.696
aAnatomic resection includes left or right lobectomy, extended left/right lobectomy, or lateral segmetectomy; combination with other hepatectomy methods is
excluded; bEarly recurrence: less than 4 months after the hepatectomy for the first liver metastasis.
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tional reserve was adequate [24]; however, the precise in-
fluence of the location of liver metastasis is rarely
evaluated and is not well described. Takasaki et al. intro-
duced the Glissonean pedicle approach for anatomic re-
section in 1986. This approach can define the sections
simply by clamping the extrahepatic pedicle [25]. In our
study, central metastasis was defined as a metastatic lesion
involving the area between the first and second generation
of hepatic bifurcation. Sometimes, a lesion adjacent to the
hepatic hilum, especially if it is large or irregularly shaped,
may span both hepatic lobes or may involve more than
one Couinaud segment.Figure 1 Recurrence-free survival (A) and overall survival (B) of liver rIn this study, there was no difference in the status of the
primary tumor between the two groups, although gender
distribution and presence of initial extrahepatic metastases
differed between the groups. Patients with central metas-
tases tended to have multiple lesions, involvement of mul-
tiple segments of the liver, bilobar distribution, and larger
tumor size. These features were not related to synchron-
icity or tumor differentiation but definitely increased the
difficulty of surgical treatment. We found that patients
with central liver metastasis tended to have earlier recur-
rence than did patients with peripheral metastases and
had markedly shorter survival (16.1 ± 1.9 vs. 43.0 ± 3.2
months, P < 0.001). When patients with CRLM underwentesection for central and peripheral liver metastases.





P values 5-year overall
survival (%)
P values




Male 89 19.5 0.699 31.5 0.449
Female 70 26.2 37.7
Location of the primary tumor(s)
Transverse colon 18 6.1 0.020 16.7 0.014
Other area (inclusive of synchronous) 141 24.4 36.4
Primary tumor staging
T1, T2, or T3 71 29.0 0.057 42.9 0.017
T4 88 17.3 27.3
Regional lymph node metastasis
Negative 32 41.7 0.002 48.4 0.004
Positive 127 17.7 30.7
Primary extrahepatic metastasis
Negative 141 25.1 0.000 37.9 0.000
Positive 18 0.0 5.6
Associated risky presentation(s)
Negative 138 23.5 0.424 38.0 0.047
Positive 21 15.1 9.5
Interval of liver metastasis
Metachronous 55 38.9 0.001 48.1 0.001
Synchronous 104 13.8 26.9
Involved hepatic segment(s)
Single 59 27.7 0.054 40.7 0.040
Multiple 100 19.3 30.3
Metastatic tumor distribution
Unilobar 114 24.1 0.193 37.2 0.200
Bilobar 45 18.2 26.7
Metastatic tumor location
Peripherally located 135 25.0 0.017 38.8 0.002
Centrally located 24 8.3 8.3
Maximal diameter of the largest metastasis
<5 cm 129 24.5 0.122 38.8 0.008
≥5 cm 30 13.9 13.8
Number of liver metastasis
Solitary 101 30.0 0.000 40.6 0.001
Multiple 58 9.0 22.8
Differentiation of metastatic tumor
Well differentiated 15 43.1 0.219 (well vs. moderately) 50.0 0.231
(well vs. moderately)
Kuo et al. World Journal of Surgical Oncology  (2015) 13:92 Page 6 of 12
Table 4 Univariate analysis of prognostic factors on recurrence-free and overall survival (Continued)




Poorly differentiated 6 0.0 0.004 (well vs. poorly) 0.0 0.000 (well vs. poorly)
Mucinous adenocarcinoma
Yes 13 23.1 0.813 38.5 0.922
No 146 22.4 33.8
Neoadjuvant chemotherapy for liver metastasis
Yes 15 20.0 0.677 35.7 0.477
No 144 22.8 20.0
Anatomic resection for liver metastasis
Yes 32 19.5 0.598 38.8 0.699
No 127 23.2 33.1
Resection margin of metastatic tumor
≥10 mm 31 40.2 0.013 58.1 0.002
<10 mm and involved 128 18.2 28.4
Recurrence after liver resection
Early recurrence (<4 months) 33 0.0 0.000
Late recurrence (≥4 months) 89 24.7
Involved organ(s) while recurrent
Confined in liver, lung or both 38 0.0 0.605 26.3 0.027
Other distant organ(s) 84 1.2 14.3
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tention to functional anatomy of the liver. This approach
may be associated with better surgical outcomes and prog-
nosis, but there remains some controversy [22,23,26-29].
In general, there was no benefit from anatomic resection
without adequate margins of resection in patients with
CRLM.
Based on the recent reports, the 5-year recurrence-free




Factors of primary status
Nodal involvement 0.018 1.847 (1
Primary extrahepatic metastasis NS -
Factors of liver metastasis
Synchronous presentation 0.024 1.627 (1
Centrally located type NS -
Multiple lesions 0.018 1.601 (1
Poorly differentiation 0.029 2.899 (1
Factors after liver resection
Resection margin < 10 mm NS -
NS, not significant.is 28% to 58% for patients with CRLM after liver resection
(Table 6) [4,6,23,30-32]. In the present study, recurrence
after hepatectomy occurred in 122 patients (76.7%) and re-
sulted in further mortality. We found that significant risk
factors for recurrence in patients with CRLM who under-
went liver resection included centrally located metastasis,
primary tumor located in the transverse colon, metastasis in
regional lymph nodes, primary extrahepatic metastasis, syn-
chronous metastasis, multiple and poorly differentiatedl (RFS) and of overall survival (OS) after liver resection
5-year OS
ratio (CI 95%) P values Hazard ratio (CI 95%)
.111 to 3.071) 0.010 1.975 (1.177 to 3.313)
0.026 1.870 (1.079 to 3.240)
.067 to 2.482) 0.007 1.775 (1.168 to 2.697)
0.036 1.705 (1.034 to 2.810)
.083 to 2.367) NS -
.114 to 7.545) 0.000 9.284 (3.442 to 25.042)
0.019 1.954 (1.118 to 3.414)
Figure 2 Recurrence-free survival after liver resection in relation to independent significant prognostic factors. (A) Regional lymph node(s)
metastasis. (B) Synchronous versus metachronous lesions. (C) Number of hepatic metastatic lesions. (D) Grade of liver metastasis. Kaplan-Meier survival
curves were plotted.
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gin <10 mm. These factors might differ from those de-
scribed in other studies because of differences in patient
populations and inclusion criteria [30,31,33-38].
Adequacy of margins of resection has been shown to be
an important and significant prognostic factor in hepatec-
tomy; a clear margin >1 cm offered the best surgical out-
come [18-20,37]; however, even a surgical margin of <1
cm should be considered in patients with CRLM if a 1-cm
margin is impossible because of the size or location of the
metastasis [22,26]. To date, no other single modality or
treatment is superior to surgical resection; thus, it should
be performed to improve the long-term survival [32]. In
our multivariate analysis, patients with central metastases
tended to have inadequate margins of resection, an inde-
pendent prognostic factor, in comparison to those with
peripheral lesions (41.7% vs. 14.8%, P = 0.003); however,both margins of resection and tumor location were inde-
pendent significant prognostic factors.
There is no consensus about the definition of meta-
chronous disease. Synchronous metastases were defined
as metastatic lesions detected by preoperative examina-
tions or during resection of the primary cancer, and
metachronous metastases were defined as cancer arising
at different times (from 3 months to 1 year) after diag-
nosis of the primary tumors [39]. With the advance of
health screening and preoperative diagnostic tools, the
synchronous lesion can be identified more accurately. In
this study, metachronous metastases were defined with
liver lesions at the interval of 3 months or more [22,23].
The patients with synchronous lesions tended to have
higher CEA level, multiple lesions, and distant metasta-
ses if recurrence. The patients in the metachronous
group experienced better 5-year recurrence-free and
Figure 3 Comparison of overall survival after liver resection based on the independent significant prognostic factors. (A) Regional
lymph node(s) metastasis. (B) Primary extrahepatic metastasis. (C) Synchronous versus metachronous metastases. (D) Grade of liver metastasis.
(E) Resection margin of hepatectomy. Kaplan-Meier survival curves were plotted and examined by log-rank test between the two groups.
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Table 6 Long-term outcomes after hepatectomy for CRLM
Author Year Number of resection 5-year RFS (%) 5-year OS (%)
Ueno [30] 2000 85 21 28
Choti [4] 2002 133 19 58
Abdalla [6] 2004 358 - 58
Adam [23] 2004 138 22 33
Tsai [31] 2006 155 16.8 41.1
Are [32] 2007 1,019 - 37
Current series 2013 159 22.4 34.2
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of dissemination and the tendency of leading to worse
prognosis in the synchronous group of patients [31].
Higher anastomotic leakage rate after simultaneous re-
section of synchronous colorectal liver metastasis was
disclosed in a recent study [40]. Excessive surgical stress
resulted from longer operative time and more blood loss
was possibly correlated with postoperative complica-
tions. Although one patient with peripheral and syn-
chronous metastatic tumor died in the hospital because
of sepsis from leakage at the anastomotic site, there was
no definite intraoperative or postoperative complication
from hepatic resection in our series.
It is interesting that when we selected the subgroup of
patients with primary tumors of the transverse colon,
this characteristic was shown by univariate analysis to be
a significant risk factor in recurrence-free and overall
survival. Hansen and Jess reported that cancers arising
in the right-sided colon, and especially those arising in
the transverse colon, had worse prognosis than did those
arising in the left-sided colon [41]. Further basic investi-
gation is needed to clarify the essential cellular and mo-
lecular mechanisms.
Patients with unresectable liver lesions benefited
from hepatectomy after downstaging management [23].
Neoadjuvant chemotherapy can be applied to reduce
the extent of metastasis with respect to tumor size, dis-
tribution, and numbers, thus improving the resectabil-
ity [10-13]. Adam et al. proposed strategies to treat
primary unresectable CRLM and methods to achieve
downstaging as well as improvement in long-term out-
come [14]. Systemic chemotherapy and/or targeted
therapy are the standard protocol in both neoadjuvant
therapy and sequential combination therapy after sur-
gery [42,43]. However, few patients (n = 15) received
neoadjuvant chemotherapy with 5-fluorouracil-based
regimens, and most of them experienced disease pro-
gression in this study. The influence of neoadjuvant
chemotherapy on prognosis could not be accurately an-
alyzed in this study because of limited case numbers.
The protocol was changed with update chemotherapy/
targeted therapy regimens in our institute, and the roleof central liver metastasis will be followed and analyzed
with reducing bias statistical tools in the future. Be-
cause most cases of centrally located hepatic lesions
were advanced, preoperative information can be pro-
vided more accurately by updating preoperative evalua-
tions and newly developed techniques. Preoperative
portal vein embolization to increase liver functional re-
serve is another option, although this technique is not
yet widely applied in clinical practice [44]. Further
studies involving neoadjuvant chemotherapy or portal
embolization for downstaging and improving resect-
ability will be evaluated.
In addition to patients benefiting from partial hepatic
resection for hepatic metastases, some specific categories
of patients with lung metastases from colorectal cancer
can benefit from pulmonary resection [45-47]. However,
Adam et al. report that hepatectomy for CRLM com-
bined with lymphadenectomy does not benefit patients
with involvement of distant lymph nodes, even when the
disease is responsive to neoadjuvant chemotherapy [48].
That is to say, the impact of metastasis in CRC varies
with the organs involved.Conclusions
In summary, central location of liver metastasis in CRC
represented an independent significant prognostic factor
for survival after hepatectomy. It affected the surgical
outcome and was associated with early recurrence.
Therefore, revision of treatment protocol such as newer
chemotherapy regiment for downstaging for this higher
risk group should be considered.Competing interests
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